Dublin, Ireland (PRWEB) March 25, 2013
This latest report analyzes clinical trial trends and the evolution of several therapeutics areas within cellular therapy [orthopedic, skin/wound care, cardiovascular, and CNS disorders] and presents the current status of every single program within the preclinical through the various clinical trial phases and onto commercialization. We also present the breakout of clinical trials in the bona fide cellular therapy sector with respect to geographic breakout, breakout by type of cells utilized, and disease classes interrogated.
Select Biosciences has also provided a detailed quantitative analysis of the cord blood field as it is rapidly evolving. The report's coverage provides hard numbers on sizes of the various registries, the TNC breakouts of banked units, detailed cost breakouts for banking as well as HSCTs utilizing cord blood. Furthermore, given the author's global footprint, they've been able to compare the EU and US markets side-by-side in this analysis.
ATMP regulatory guidelines governing the marketing authorization of cellular therapeutics in the European Union are also given. Details on the statute as well as implications to companies seeking to navigate this space are provided.
Presented in this Report
Copyright©2012 Vocus, Inc.
All rights reserved